A critical look at why most intravenously delivered stem cells fail to reach damaged tissues and a homing-based alternative.
Key Takeaways
- Regenerative medicine industry has a confession it would rather not make
- This is not a fringe problem or a manufacturing flaw
- Standard MSCs are structurally fragile and immunologically conspicuous